

Disclosure Purpose: 21-19451

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- 2. **What is the manuscript title?**
Effectiveness of COVID-19 Vaccines against the Omicron (B.1.1.529) Variant of Concern
- 3. **Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-19451

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Duration of Protection of COVID-19 Vaccines Against Mild and Severe Disease.
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-19451

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Duration of Protection of COVID-19 Vaccines Against Mild and Severe Disease
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-19451

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- 2. **What is the manuscript title?**
Effectiveness of COVID-19 Vaccines against the Omicron (B.1.1.529) Variant of Concern
- 3. **Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-19451

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- 2. **What is the manuscript title?**
Effectiveness of COVID-19 Vaccines against the Omicron (B.1.1.529) Variant of Concern
- 3. **Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-19451

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- 2. **What is the manuscript title?**
Duration of Protection of COVID-19 Vaccines Against Mild and Severe Disease
- 3. **Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-19451

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Duration of Protection of COVID-19 Vaccines Against Mild and Severe Disease
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-19451

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- 2. **What is the manuscript title?**
Durability of Protection Against Future SARS-CoV-2 Infection Following Vaccination and Prior Infection in UK Healthcare Workers (the SIREN Cohort)
- 3. **Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-19451

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
GlaxoSmithKline	Grant / Contract	Other - employing organisation
<i>Recipient Name:</i> public health england <i>Grant / Contract Description:</i> Seasonal influenza - Zanamivir <i>Additional Information:</i> My employer's predecessor organisation Public Health England has received funding from GSK. for a research project related to analysis of observational data for seasonal influenza and antiviral treatment (zanamivir). This preceded and had no relation to COVID-19. However, i have had no personal role in this work or received any funding from this project.		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
No.
- What is the manuscript title?
Duration of Protection of COVID-19 Vaccines Against Mild and Severe Disease
- Are you the corresponding author?
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-19451

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- 2. **What is the manuscript title?**
Effectiveness of COVID-19 Vaccines against the Omicron (B.1.1.529) Variant of Concern
- 3. **Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-19451

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Bill and Melinda Gates Foundation	Grant / Contract	Self
<p><i>Recipient Name:</i> Imperial College London <i>Grant / Contract Description:</i> Grant to run the Vaccine Impact Modelling Consortium <i>Additional Information:</i> I am PI. This grant did not support the work on this paper.</p>		
Community Jameel	Grant / Contract	Self
<p><i>Recipient Name:</i> Imperial College London <i>Grant / Contract Description:</i> Philanthropic donation to found the Jameel Institute at Imperial <i>Additional Information:</i> I am PI. See https://www.communityjameel.org/ for info about CJ</p>		
GAVI Alliance	Grant / Contract	Self
<p><i>Recipient Name:</i> Imperial College London <i>Grant / Contract Description:</i> Funding for the Vaccine Impact Modelling Consortium, run by Imperial College <i>Additional Information:</i> I am PI. This grant did not fund the work on this paper.</p>		
Janssen Biotech	Grant / Contract	Self
<p><i>Recipient Name:</i> Imperial College London <i>Grant / Contract Description:</i> Grant to model a candidate antiviral agent for dengue <i>Additional Information:</i> Co-I. Not related to COVID-19.</p>		
Medical Research Council	Grant / Contract	Self
<p><i>Recipient Name:</i> Imperial College London <i>Grant / Contract Description:</i> Project grant under UKRI COVID rapid response scheme <i>Additional Information:</i> I am co-I</p>		
Medical Research Council	Grant / Contract	Self
<p><i>Recipient Name:</i> Imperial College London <i>Grant / Contract Description:</i> Centre Grant for the MRC Centre for Global Infectious Disease Analysis <i>Additional Information:</i> I am PI</p>		
National Institute for Health Research	Grant / Contract	Self
<p><i>Recipient Name:</i> Imperial College London <i>Grant / Contract Description:</i> Unit funding for the Health Protection Research Unit for Modelling and Health Economics <i>Additional Information:</i> I am PI</p>		
Wellcome Trust	Other	Self
<p><i>Category:</i> Other <i>Description:</i> Panel member <i>Additional Information:</i> I have sat on a number of grant and advisory panels for the Wellcome trust. An honorarium and travel costs are usually paid.</p>		
World Health Organization	Other	Self
<p><i>Category:</i> Other <i>Description:</i> Advisor <i>Additional Information:</i> I advise the WHO in a number of roles. None are remunerated, though travel costs are sometimes paid (not since 2019)</p>		

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
No.
- What is the manuscript title?
Effectiveness of COVID-19 Vaccines against the Omicron (B.1.1.529) Variant of Concern
- Are you the corresponding author?

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-19451

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- 2. **What is the manuscript title?**
Duration of Protection of COVID-19 Vaccines Against Mild and Severe Disease
- 3. **Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-19451

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- 2. **What is the manuscript title?**
COVID-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant
- 3. **Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-19451

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- 2. **What is the manuscript title?**
Effectiveness of COVID-19 Vaccines Against Omicron variant
- 3. **Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-19451

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- 2. **What is the manuscript title?**
Duration of Protection of COVID-19 Vaccines Against Mild and Severe Disease
- 3. **Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-19451

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- 2. **What is the manuscript title?**
Effectiveness of COVID-19 Vaccines against the Omicron (B.1.1.529) Variant of Concern
- 3. **Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-19451

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Gilead Sciences	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i>		<i>Description:</i> Development of slideset for HIV and quality of life

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Effectiveness of COVID-19 Vaccines against the Omicron (B.1.1.529) Variant of Concern
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-19451

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Effectiveness of COVID-19 Vaccines against the Omicron (B.1.1.529) Variant of Concern
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-19451

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- 2. **What is the manuscript title?**
Duration of protection of BNT162b2ChAdOx1-SmRNA-1273COVID-19 vaccines against mild and severe disease in England
- 3. **Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-19451

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

COVID-19 vaccine effectiveness against the Omicron (B. 1.1.529) variant

3. **Are you the corresponding author?**

Yes.

a. **Please list the other authors' names here.**

Nick Andrews PhD1,2,* Julia Stowe PhD1,* Freja Kirsebom PhD1, Samuel Toffa PhD1, Tim Rickeard1, Eileen Gallagher PhD1, Charlotte Gower DPhil1, Meaghan Kall1, Natalie Groves MSc1, Anne-Marie O'Connell1, David Simons1, Paula B. Blomquist1, Asad Zaidi1, Sophie Nash1, Nurin Iwani Binti Abdul Aziz1, Simon Thelwall1, Gavin Dabrera MBBS, FFPH1, Richard Myers1, MRCPCH1,3, Gayatri Amirthalingam MFPH1,2, Saheer Gharbia1, Jeffrey C. Barrett D Phil4, Richard Elson1, Shamez N Ladhani PhD, MRCPCH1,3, Neil Ferguson5,6, Maria Zambon PhD, FRCPath1,6, Colin NJ Campbell MPH, FFPH1,2, Kevin Brown MRCP FRCPath1,2, Susan Hopkins FRCP, FFPH1,7, Meera Chand MRCP, FRCPath1,8, Mary Ramsay MBBS, FFPH1,2, Jamie Lopez Bernal PhD ,MBBS 1,2,6

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-19451

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- 2. **What is the manuscript title?**
Effectiveness of COVID-19 Vaccines against the Omicron (B.1.1.529) Variant of Concern
- 3. **Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-19451

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- 2. **What is the manuscript title?**
Effectiveness of COVID-19 Vaccines against the Omicron (B.1.1.529) Variant of Concern
- 3. **Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-19451

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Effectiveness of COVID-19 Vaccines against the Omicron (B.1.1.529) Variant of Concern
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-19451

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Pfizer	Grant / Contract	Other - Department
Recipient Name: Public Health England Grant / Contract Description: Post-marketing surveillance reports on pneumococcal and meningococcal infection		Recipient Type: Institution Grant / Contract Purpose: Other - Risk Management Strategy Additional Information: The Immunisation Department has provided vaccine manufacturers (including Pfizer) with post-marketing surveillance reports on pneumococcal and meningococcal infection which the companies are required to submit to the UK Licensing authority in compliance with their Risk Management Strategy. A cost recovery charge is made for these reports..

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
No.
- What is the manuscript title?
Effectiveness of COVID-19 Vaccines against the Omicron (B.1.1.529) Variant of Concern
- Are you the corresponding author?
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-19451

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Covid-19 Vaccine Effectiveness against 3 the Omicron (B.1.1.529) Variant
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-19451

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Biotechnology and Biological Sciences Research Council	Grant / Contract	Self
<i>Recipient Name:</i> David Simons <i>Grant / Contract Description:</i> PhD research funding and stipend <i>Additional Information:</i> [grant number BB/M009513/1]		<i>Recipient Type:</i> Individual <i>Grant / Contract Purpose:</i> Research

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Effectiveness of COVID-19 Vaccines against the Omicron (B.1.1.529) Variant of Concern
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-19451

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Effectiveness of COVID-19 Vaccines against the Omicron (B.1.1.529) Variant of Concern
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-19451

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Duration of Protection of COVID-19 Vaccines Against Mild and Severe Disease
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-19451

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- 2. **What is the manuscript title?**
Effectiveness of COVID-19 Vaccines against the Omicron (B.1.1.529) Variant of Concern
- 3. **Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-19451

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- 2. **What is the manuscript title?**
Effectiveness of COVID-19 Vaccines against the Omicron (B.1.1.529) Variant of Concern
- 3. **Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-19451

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
International Society for Influenza and other Respiratory Virus Diseases (ISIRV)	Fiduciary Officer	Self
<i>Official Title:</i> Chair of ISIRV		<i>Position Description:</i> Chair position on ISIRV board
<i>Additional Information:</i> Charitable organisation, registered charity in the UK. Unremunerated position. Member of the board since 2016/2017.		

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Effectiveness of COVID-19 Vaccines against the Omicron (B.1.1.529) Variant of Concern
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

